Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap
Primary Purpose
End Stage Renal Disease (ESRD)
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
ClearGuard HD End Cap
Sponsored by
About this trial
This is an interventional treatment trial for End Stage Renal Disease (ESRD)
Eligibility Criteria
Inclusion Criteria:
- All patients dialyzing with a central venous catheter
Exclusion Criteria:
- Known allergy to chlorhexidine
Sites / Locations
- DaVita Clinical Research
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Treatment
Control
Arm Description
ClearGuard HD End Cap
Tego® connector with the CurosTM for Tego disinfecting port protector
Outcomes
Primary Outcome Measures
Positive Blood Cultures (PBC's) Per 1,000 Central Venous Catheter (CVC)-Days
This was calculated by dividing the cumulative number of PBCs by cumulative time at-risk as follows.
The National Healthcare Safety Network (NHSN) Center for Disease Control (CDC) 21-day outpatient hemodialysis patient rule is as follows: A PBC is considered a new event and counted only if it occurred 21 days or more after a previously reported PBC in the same patient; new PBC events are based on blood cultures drawn as an outpatient or within one calendar day after a hospital admission. Following a PBC additional same-type events were counted beginning 21 days following the initial event; the CVC-days were counted during this period. The CVC-days were calculated by summing the number of days each patient was at-risk of accruing a PBC. This analysis included all subjects that participated in the study that were not otherwise censored to more accurately count CVC-days.
Secondary Outcome Measures
Full Information
NCT ID
NCT02593149
First Posted
October 29, 2015
Last Updated
February 5, 2019
Sponsor
Pursuit Vascular, Inc.
Collaborators
Davita Clinical Research
1. Study Identification
Unique Protocol Identification Number
NCT02593149
Brief Title
Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap
Official Title
Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap
Study Type
Interventional
2. Study Status
Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
November 2015 (Actual)
Primary Completion Date
November 2016 (Actual)
Study Completion Date
November 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pursuit Vascular, Inc.
Collaborators
Davita Clinical Research
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
To assess blood stream infections in participants using two FDA-cleared devices: ClearGuard HD end caps compared to the Tego® connector with the CurosTM for Tego disinfecting port protector.
Detailed Description
Prospective, cluster-randomized, open-label, post market, comparative effectiveness evaluation with facilities participating for up to 13 months.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End Stage Renal Disease (ESRD)
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1902 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Treatment
Arm Type
Experimental
Arm Description
ClearGuard HD End Cap
Arm Title
Control
Arm Type
No Intervention
Arm Description
Tego® connector with the CurosTM for Tego disinfecting port protector
Intervention Type
Device
Intervention Name(s)
ClearGuard HD End Cap
Intervention Description
The ClearGuard HD end cap elutes chlorhexidine acetate into the hemodialysis hub
Primary Outcome Measure Information:
Title
Positive Blood Cultures (PBC's) Per 1,000 Central Venous Catheter (CVC)-Days
Description
This was calculated by dividing the cumulative number of PBCs by cumulative time at-risk as follows.
The National Healthcare Safety Network (NHSN) Center for Disease Control (CDC) 21-day outpatient hemodialysis patient rule is as follows: A PBC is considered a new event and counted only if it occurred 21 days or more after a previously reported PBC in the same patient; new PBC events are based on blood cultures drawn as an outpatient or within one calendar day after a hospital admission. Following a PBC additional same-type events were counted beginning 21 days following the initial event; the CVC-days were counted during this period. The CVC-days were calculated by summing the number of days each patient was at-risk of accruing a PBC. This analysis included all subjects that participated in the study that were not otherwise censored to more accurately count CVC-days.
Time Frame
Through the 13-month intervention period.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
All patients dialyzing with a central venous catheter
Exclusion Criteria:
Known allergy to chlorhexidine
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Steven M Brunelli, MD, MSCE
Organizational Affiliation
DaVita Clinical Research / DaVita HealthCare Partners
Official's Role
Principal Investigator
Facility Information:
Facility Name
DaVita Clinical Research
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55404
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
29472415
Citation
Brunelli SM, Van Wyck DB, Njord L, Ziebol RJ, Lynch LE, Killion DP. Cluster-Randomized Trial of Devices to Prevent Catheter-Related Bloodstream Infection. J Am Soc Nephrol. 2018 Apr;29(4):1336-1343. doi: 10.1681/ASN.2017080870. Epub 2018 Feb 22.
Results Reference
result
Links:
URL
http://pursuitvascular.com
Description
Pursuit Vascular website
Learn more about this trial
Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap
We'll reach out to this number within 24 hrs